<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220880</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR5010</org_study_id>
    <nct_id>NCT03220880</nct_id>
  </id_info>
  <brief_title>Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures</brief_title>
  <official_title>Clinical Characteristics of Intranasal Dexmedetomidine for Sedation in Children Undergoing Non-painful Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Healthcare of Atlanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Pittsburgh of UPMC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dartmouth College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Santa Clara Valley Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNC Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>WakeMed Health &amp; Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Childrenâ€™s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Specific Aim 1: To describe the adequacy of sedation associated with different regimens of IN
      DEX in children undergoing non-painful procedures. This aim will test the working hypothesis
      that IN DEX regimens are effective for producing sedation adequate for completion of
      non-painful procedures in children.

      Specific Aim 2: To describe the temporal characteristics associated with varied regimens of
      IN DEX in children undergoing non-painful procedures, such as time to onset of adequate
      sedation; time to procedure start; and time from procedure end to meeting discharge criteria.
      This aim will test the working hypothesis that IN DEX regimens have temporal characteristics
      that are favourable for sedating children for non-painful procedures.

      Specific Aim 3: To describe the adverse events associated with varied regimens of IN DEX in
      children undergoing non-painful procedures. This aim will test the working hypothesis that IN
      DEX regimens have a low incidence of adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine (DEX) is an alpha-2 receptor agonist with sedative, anxiolytic, and
      analgesics properties. DEX has been used extensively for sedation in children to facilitate
      different non-painful procedures, such magnetic resonance imaging (MRI), auditory brainstem
      response (ABR) tests, and computed tomography (CT) scans. In particular, DEX can be
      administered by the intranasal (IN) route. Intranasal administration has the benefits of
      being both effective and needle-free, of which the latter makes it less distressing to
      children compared to sedatives administered by the intravenous (IV) route. There is a gap of
      knowledge, however, regarding the ideal regimen of IN DEX for providing optimal procedural
      sedation in children undergoing non-painful procedures. There is a large variation in
      practice using IN DEX, both regarding the dose and the use of adjunct medications. It is also
      unknown whether regimens should vary based on patient factors such as age. There is no clear
      evidence to define best practice when using IN DEX to provide sedation in this population to
      achieve the desired outcomes most relevant to clinicians. The rationale of the proposed
      investigation is that by conducting an exploratory study to measure clinical outcomes
      associated with IN DEX, the investigators can begin to identify trends and differences that
      will lay the foundation for randomized clinical trials to identify the ideal regimen for IN
      DEX when providing sedation for non-painful procedures. This will then allow the
      investigators to compare IN DEX, at its best, to other sedatives so that the sedative and
      regimen associated with the best outcomes relevant to sedation of children undergoing
      non-painful procedures can be determined.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adequacy of sedation</measure>
    <time_frame>1 hour</time_frame>
    <description>Pediatric Sedation State Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of adequate sedation</measure>
    <time_frame>1 hour</time_frame>
    <description>Time in minutes after administration of IN DEX to achieve a University of Michigan Sedation Scale (UMSS) score of 3 or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>2 hours</time_frame>
    <description>Time in minutes after procedure end to achieving Modified Aldrete Scoring System (MASS) score of 9 or greater, or baseline MASS score.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 hours</time_frame>
    <description>Adverse events and/or required interventions (e.g. cardiovascular, airway) required</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Dexmedetomidine</condition>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Intranasal dexmedetomidine</arm_group_label>
    <description>Intranasal dexmedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal dexmedetomidine</intervention_name>
    <description>Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg</description>
    <arm_group_label>Intranasal dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children undergoing sedation using intranasal dexmedetomidine for non-painful procedures.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 2 months to 17 years (i.e. before their 18th birthday)

          -  Child will be receiving intranasal dexmedetomidine as part of their usual medical care

          -  Child will be undergoing a non-painful medical procedure, which includes (but is not
             limited to): MRI, CT scans, ABR/BAER, echocardiograms, and EEGs.

        Exclusion Criteria:

          -  Known allergy to dexmedetomidine

          -  Known abnormal renal or hepatic function

          -  Known cardiac conduction abnormality or heart block

          -  Current use of digoxin or beta-blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S Tsze, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel S Tsze, MD, MPH</last_name>
    <phone>212-305-9825</phone>
    <email>dst2141@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Santa Clara Valley Medical Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Baier, MD</last_name>
      <email>Nicole.Baier@hhs.sccgov.org</email>
    </contact>
    <investigator>
      <last_name>Nicole Baier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Sulton, MD</last_name>
      <email>carmen.sulton@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Carmen Sulton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth College</name>
      <address>
        <city>Hanover</city>
        <state>New Hampshire</state>
        <zip>03755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNC Children's Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janey Phelps, MD</last_name>
      <email>jphelps@aims.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Janey Phelps, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Crego, PhD RN</last_name>
      <email>nancy.crego@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy Crego, PhD RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WakeMed Health &amp; Hospitals</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Davis, RN</last_name>
      <email>MIDAVIS@wakemed.org</email>
    </contact>
    <investigator>
      <last_name>Michelle Davis, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joanna Paquin, MD</last_name>
      <email>Joanna.Rosing@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Joanna Paquin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Mahmoud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>April Hollenbeck, PA-C</last_name>
      <email>April.hollenbeck@chp.edu</email>
    </contact>
    <investigator>
      <last_name>April Hollenbeck, PA-C</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabela Cajiao-Angelelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rotem Elitsur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amber Rogers, MD</last_name>
      <email>aprogers@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Amber Rogers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>April 7, 2018</last_update_submitted>
  <last_update_submitted_qc>April 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Daniel Sing-Kwong Tsze</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics at CUMC</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Sedation</keyword>
  <keyword>Pediatric</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

